Biotia develops AI-driven genomic assays and a global pandemic early warning system to enhance the detection and management of infectious diseases. Their technology integrates local health data with climate information to provide actionable insights, improving diagnostic accuracy and outbreak response in underserved regions.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current infectious disease detection methods often suffer from high failure rates and limited utility, particularly in identifying pathogens in immunocompromised patients or those with complex infections. Existing technologies may lack the sensitivity and specificity needed for accurate and timely diagnosis, hindering effective treatment and outbreak response. Furthermore, traditional lab methods can be slow and may require culturing, which is not always feasible for certain pathogens.
Solution
Biotia offers a suite of genomics-based assays and a pandemic early warning system that leverage AI to improve infectious disease detection and management. Their BIOTIA-ID and BIOTIA-ID Urine products are comprehensive diagnostic assays with extensive clinical validation, designed to overcome the limitations of current technologies. GeoSeeq, their global pandemic early warning system, integrates local lab data with climate information to detect, predict, mitigate, and contain outbreaks before they escalate. By fortifying local labs with modern sequencing technology and AI-driven insights, Biotia enables high-resolution mapping of health and disease, facilitating proactive interventions and improved patient outcomes.
Target Audience
Biotia's products target clinicians and researchers, particularly those focused on infectious diseases, clinical diagnostics, and public health, as well as global health organizations and underserved communities seeking advanced diagnostic and early warning systems.
Features
- BIOTIA-ID: A comprehensive genomics-based assay for infectious disease diagnostics, suitable for immunocompromised patients and complicated infections.
- BIOTIA-ID Urine: A novel diagnostic assay for urinary tract infections with high sensitivity, specificity, and extensive characterization of disease-causing pathogens.
- GeoSeeq: A global pandemic early warning system that detects, predicts, and helps contain outbreaks by integrating local lab data with climate information.
- Community-driven AI: Integrates climate and health data to drive agency actions, diagnostics, vaccines, and therapeutics.
- Modern sequencing technology: Fortifies local labs in diagnostic deserts, enabling them to leapfrog legacy diagnostics.
- Clinically validated metagenomics tool (BIOTIA-DX): Identifies organisms with higher sensitivity than culture or qPCR.